Biosimilar Patient Experience a Focus at NASP 2025

Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksSeveral presenters at the NASP 2025 Annual Meeting & Expo, in Denver, discussed transitioning patients from adalimumab (Humira, AbbVie) to various biosimilars, as 10 adalimumab biosimilars are currently available in the United States.Acknowledging patient concerns about biosimilar transitions is critical, commented Cate Lockhart, PharmD, PhD, the chief science officer at the Academy of Managed Care P